⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12477741 | 0.60 | CA1 (0.33) | — | |
| SCHEMBL276691 | 0.58 | STS (0.38) | — | |
| SCHEMBL276211 | 0.58 | STS (0.35) | — | |
| SCHEMBL1815150 | 0.58 | CYP1A2 (0.43) | — | |
| SCHEMBL1082812 | 0.58 | CYP2B6 (0.42) | — | |
| SCHEMBL22915707 | 0.57 | STS (0.44) | — | |
| SCHEMBL3073551 | 0.57 | — | — | |
| SCHEMBL28613752 | 0.56 | CYP2B6 (0.41) | — | |
| SCHEMBL29937847 | 0.56 | CYP2B6 (0.41) | — | |
| SCHEMBL27328255 | 0.56 | CYP2B6 (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2004087643-A1 | DEFORMYLASE INHIBITOR, PROCESS FOR PREPARING THE SAME, AND ANTIBACTERIAL COMPOSITION COMPRISING THE SAME | PROMEDITECH INC. (KR) | 2004-10-14 | — | — | WO | claimed |
| WO-2023102472-A1 | ANTIVIRAL PRODRUGS AND FORMULATIONS THEREOF | THE SCRIPPS RESEARCH INSTITUTE (US) | 2023-06-08 | — | — | WO | disclosed |
| CN-110234635-B | Novel substituted benzimidazole derivatives as D-amino oxidase (DAAO) inhibitors | 宇凤·简·曾 | 2023-03-10 | — | — | CN | disclosed |
| CN-115768762-A | Compounds for the treatment of huntington's disease | PTC医疗公司 | 2023-03-07 | — | — | CN | disclosed |
| CN-115397821-A | Bifunctional molecules containing an E3 ubiquitin ligase binding moiety linked to a BCL6 targeting moiety | 阿尔维纳斯运营股份有限公司 | 2022-11-25 | — | — | CN | disclosed |
| CN-115151304-A | Small molecule interferon gene stimulating factor (STING) antagonists | 库拉德夫制药私人有限公司 | 2022-10-04 | — | — | CN | disclosed |
| CN-114867727-A | TAU protein targeting compounds and related methods of use | 阿尔维纳斯运营股份有限公司 | 2022-08-05 | — | — | CN | disclosed |
| US-11364240-B2 | Pyruvate kinase activators for use in treating blood disorders | AGIOS PHARMACEUTICALS, INC. (US) | 2022-06-21 | — | — | US | disclosed |
| CN-114437105-A | Inhibitors of receptor interacting protein kinase 1 | 戴纳立制药公司 | 2022-05-06 | — | — | CN | disclosed |
| CN-114286671-A | Compositions and methods for biological delivery vehicles | DNALite治疗学公司 | 2022-04-05 | — | — | CN | disclosed |
| US-20050113580-A1 | Amide compounds and methods of using the same | SMITHKLINE BEECHAM CORP | 2005-05-26 | — | — | US | disclosed |
| US-20050107444-A1 | Amide compounds and methods of using the same | GLAXOSMITHKLINE LLC | 2005-05-19 | — | — | US | disclosed |
| EP-1511483-A2 | METHODS OF TREATMENT WITH LXR MODULATORS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-03-09 | — | — | EP | disclosed |
| WO-2005013946-A2 | METHODS OF TREATMENT INFLAMMATORY BOWEL WITH LXR AGONISTS | GLAXO GROUP LIMITED (GB) | 2005-02-17 | — | — | WO | disclosed |
| WO-2005009383-A2 | METHODS OF TREATMENT WITH LXR AGONISTS | GLAXO GROUP LIMITED (GB) | 2005-02-03 | — | — | WO | disclosed |
| WO-2004087643-A1 | DEFORMYLASE INHIBITOR, PROCESS FOR PREPARING THE SAME, AND ANTIBACTERIAL COMPOSITION COMPRISING THE SAME | PROMEDITECH INC. (KR) | 2004-10-14 | — | — | WO | disclosed |
| EP-1379238-A1 | FAVORABLE MODULATION OF HEALTH-RELATED QUALITY OF LIFE AND HEALTH-RELATED QUALITY-ADJUSTED TIME-TO-PROGRESSION OF DISEASE IN PATIENTS WITH PROSTATE CANCER | Abbott Laboratories (US) | 2004-01-14 | — | — | EP | disclosed |
| WO-2003082198-A2 | METHODS OF TREATMENT WITH LXR MODULATORS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-10-09 | — | — | WO | disclosed |
| US-20030092757-A1 | Favorable modulation of health-related quality of life and health-related quality-adjusted time-to-progression of disease in patients with prostate cancer | ABBOTT LABORATORIES | 2003-05-15 | — | — | US | disclosed |
| WO-2002085351-A1 | FAVORABLE MODULATION OF HEALTH-RELATED QUALITY OF LIFE AND HEALTH-RELATED QUALITY-ADJUSTED TIME-TO-PROGRESSION OF DISEASE IN PATIENTS WITH PROSTATE CANCER | ABBOTT LABORATORIES (US) | 2002-10-31 | — | — | WO | disclosed |